Literature DB >> 7707549

Attenuated Mengo virus: a new vector for live recombinant vaccines.

R Altmeyer1, M Girard, S van der Werf, V Mimic, L Seigneur, M F Saron.   

Abstract

Several features make Mengo virus an excellent candidate for use as a vaccine vector. The virus has a wide host range, including rodents, pigs, monkeys, and most likely humans, and expresses its genome exclusively in the cytoplasm of the infected cell. Stable attenuated strains exist which are deleted for part of the 5' noncoding region of the genome. Here we report an attenuated Mengo virus recombinant, vLCMG4, that encodes an immunodominant cytotoxic T-lymphocyte epitope of the lymphocytic choriomeningitis virus (LCMV) nucleo-protein. vLCMG4 induced protective immunity against lethal LCMV infection after a single, low-dose immunization in BALB/c mice and elicited an LCMV-specific CD8+ cytotoxic T lymphocyte response. This demonstrates the potential of recombinant Mengo virus vaccines to confer protection against infectious diseases by the induction of cellular immune responses.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7707549      PMCID： PMC189023     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  Adenovirus-based expression vectors and recombinant vaccines.

Authors:  F L Graham; L Prevec
Journal:  Biotechnology       Date:  1992

2.  The prevalence of encephalomyocarditis virus neutralizing antibodies among various human populations.

Authors:  R B Tesh
Journal:  Am J Trop Med Hyg       Date:  1978-01       Impact factor: 2.345

3.  Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes.

Authors:  M R Castrucci; S Hou; P C Doherty; Y Kawaoka
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

4.  Antigen chimaeras of poliovirus as potential new vaccines.

Authors:  K L Burke; G Dunn; M Ferguson; P D Minor; J W Almond
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

5.  Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Authors:  J L Whitton; A Tishon; H Lewicki; J Gebhard; T Cook; M Salvato; E Joly; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

Authors:  M Sarmiento; A L Glasebrook; F W Fitch
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

7.  Engineering poliovirus as a vaccine vector for the expression of diverse antigens.

Authors:  R Andino; D Silvera; S D Suggett; P L Achacoso; C J Miller; D Baltimore; M B Feinberg
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

8.  Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B.

Authors:  M R McDermott; F L Graham; T Hanke; D C Johnson
Journal:  Virology       Date:  1989-03       Impact factor: 3.616

9.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.

Authors:  J Taylor; R Weinberg; J Tartaglia; C Richardson; G Alkhatib; D Briedis; M Appel; E Norton; E Paoletti
Journal:  Virology       Date:  1992-03       Impact factor: 3.616
View more
  15 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Mengovirus and encephalomyocarditis virus poly(C) tract lengths can affect virus growth in murine cell culture.

Authors:  L R Martin; Z C Neal; M S McBride; A C Palmenberg
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Mutational analysis of the mengovirus poly(C) tract and surrounding heteropolymeric sequences.

Authors:  L R Martin; G M Duke; J E Osorio; D J Hall; A C Palmenberg
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

Authors:  C Sedlik; M Saron; J Sarraseca; I Casal; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

5.  Epitope mapping of monoclonal antibodies raised to recombinant Mengo 3D polymerase.

Authors:  H Duque; A C Palmenberg
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

6.  Immunogenicity of recombinant classic swine fever virus CD8(+) T lymphocyte epitope and porcine parvovirus VP2 antigen coexpressed by Lactobacillus casei in swine via oral vaccination.

Authors:  Yigang Xu; Lichun Cui; Changyong Tian; Guocai Zhang; Guicheng Huo; Lijie Tang; Yijing Li
Journal:  Clin Vaccine Immunol       Date:  2011-09-21

7.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

8.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.

Authors:  M F Saron; C Fayolle; P Sebo; D Ladant; A Ullmann; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Characterization of replication-competent hepatitis A virus constructs containing insertions at the N terminus of the polyprotein.

Authors:  Y Zhang; G G Kaplan
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.